Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Monthly Macro: AI Booms, Inflation Bites, Fed Shifts

    William Blair macro analyst Richard de Chazal discusses how the Iran conflict, AI-driven investment themes from William Blair’s 46th Growth Stock Conference, persistent inflation pressures, and Kevin Warsh’s early approach as Fed chair are shaping the macro outlook for the second half of 2026.

    Listen to the podcast

  • William Blair Completes Acquisition of Inner Circle Sports

    William Blair today announced it has successfully completed its acquisition of Inner Circle Sports, a leading boutique investment bank focused on the global sports, media, and entertainment ecosystem.

    Read more

  • Concentra Group Holdings Parent, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Concentra Group Holdings Parent, Inc. (CON $29.77), a provider of occupational health services focused on treating workplace injury and illness.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures